StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by valentinemassonon Aug 10, 2020 10:35am

178 Views

Post# 31387108

RE:RE:RE:Doesn't look good.

frewil11 wrote: It is a 100% given that SZLS revenue will grow because of COVID , but will the market buy this up knowing it is not a permanent revenue source ?

SZLS is generating revenue and perhaps notoriety in Covid testing , garnering attention to the ability to process high volume of tests with a notable level of accuracy. The monies generated will be , according to Mr. Tripp , used to launch Aristotle by years end. Aristotle , if successfully launched into market , is where the real money will be.

VM.

Bullboard Posts

Anaergia expands relationship with PepsiCo